Michael Gray Net Worth

The estimated Net Worth of Michael Gray is at least $235 mil dollars as of 22 February 2023. Michael Gray owns over 9,856 units of Imara Inc stock worth over $174,495 and over the last 21 years Michael sold IMRA stock worth over $60,124.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Gray IMRA stock SEC Form 4 insiders trading

Michael has made over 12 trades of the Imara Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Michael sold 9,856 units of IMRA stock worth $46,028 on 22 February 2023.

The largest trade Michael's ever made was exercising 50,000 units of Imara Inc stock on 6 May 2013 worth over $121,500. On average, Michael trades about 6,270 units every 211 days since 2003. As of 22 February 2023 Michael still owns at least 27,610 units of Imara Inc stock.

You can see the complete history of Michael Gray stock trades at the bottom of the page.

What's Michael Gray's mailing address?

Michael's mailing address filed with the SEC is C/O IMARA, INC., 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON, MA, 02116.

Insiders trading at Imara Inc

Over the last 5 years, insiders at Imara Inc have traded over $7,889,059 worth of Imara Inc stock and bought 11,496,717 units worth $107,874,489 . The most active insiders traders include David M Mott, Lundbeck A S H y Capital Management, L.P.Ra .... On average, Imara Inc executives and independent directors trade stock every 23 days with the average trade being worth of $1,965,179. The most recent stock trade was executed by Michael Gray on 22 February 2023, trading 9,856 units of IMRA stock currently worth $46,028.

What does Imara Inc do?

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.

Complete history of Michael Gray stock trades at Curis Inc y Imara Inc

Imara Inc executives and stock owners

Imara Inc executives and other stock owners filed with the SEC include:

• Rahul D. Ballal,
  Chief Executive Officer
• Edward R. Conner,
  Director
• Enterprise Associates 14, L...,
  
• Springs Capital Management ...,
  
• Lundbeck A S H,
  10% owner
• City Capital Llc Bay City C...,
  
• Venture Investments, Llc Al...,
  10% owner
• Invest A/S Lundbeckfond,
  10% owner
• Bioscience Plc Arix Bioscie...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• James G Mc Arthur,
  Director
• Carlbay City Capital Llc Ba...,
  
• Mette Kirstine Agger,
  Director
• David P Bonita,
  Director
• Barbara Dalton,
  Director
• Sara M. Nayeem,
  Director
• David M Mott,
  Director
• Inc Pfizer Ventures (Us) Ll...,
  
• Enterprise Associates 14, L...,
  
• Michael Gray,
  CFO & COO
• Kenneth Attie,
  SVP, CMO
• Laura A Williams,
  Director
• Carl Goldfischer,
  Director
• Mark Chin,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Braden Michael Leonard,
  10% owner
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Capital Lp Commodore,
  10% owner